Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fat Grafts With Adipose-derived Regenerative Cells for Soft Tissue Reconstruction in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03806361
Recruitment Status : Active, not recruiting
First Posted : January 16, 2019
Last Update Posted : May 12, 2020
Sponsor:
Information provided by (Responsible Party):
Daniela S Tanikawa, Hospital Sirio-Libanes

Brief Summary:
Although first reports of the clinical use of adipose-derived regenerative cells (ADRC) suggest that this approach may be feasible and effective for soft tissue augmentation, there is a lack of randomized, controlled clinical trials in the literature. Hence, this study aimed to investigate whether a novel protocol for isolation of ADRC and their use in combination with fat tissue improve the long-term retention of the grafts in paediatric patients with craniofacial microsomia.

Condition or disease Intervention/treatment Phase
Craniofacial Microsomia Procedure: Fat grafts supplemented with ADRC Procedure: Structural fat grafting Not Applicable

Detailed Description:

To overcome problems associated with fat grafting, such as unpredictable clinical results and a low rate of graft survival, many innovative efforts and refinements of surgical techniques have been reported. For example, condensation of living tissue and removal of unnecessary components have been performed by centrifugation, filtration or gravity sedimentation; external mechanical force has been used to expand the recipient tissue as well as the overlying skin envelope; and a recent experimental study has suggested that repeated local injections of erythropoietin might enhance retention of grafted fat.

Based on the finding that aspirated fat tissue contains a much smaller number of adipose-derived regenerative cells (ADRC) compared with intact tissue and that these cells play pivotal roles in the adipose tissue remodeling after lipoinjection, the supplementation of fat grafts with stromal vascular fraction isolated from adipose portion of liposuction aspirates has been proposed as a method to compensate its relative deficiency of ADRC.

In the literature, there are at least three experimental studies demonstrating that supplementation of adipose progenitor cells enhances the volume or weight of surviving adipose tissue, and first reports of the clinical use of ADRC suggest that this approach may be feasible and effective for soft tissue augmentation.

However, since these studies represent level of evidence IV, which correspond to the publication of case series, there is a lack of randomized, controlled clinical trials comparing this method to current standard techniques.

Hence, this study aimed to fill this gap by investigating whether a novel protocol for isolation of ADRC and their use in combination with fat tissue improve the long-term retention of the grafts in paediatric patients with craniofacial microsomia.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, controlled, clinical trial with 2 parallel comparison groups
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Subjects will not know which treatment they will receive, outcome assessors will also be blinded.
Primary Purpose: Treatment
Official Title: Fat Grafts Supplemented With Adipose-derived Regenerative Cells for Soft Tissue Reconstruction in Children With Craniofacial Microsomia
Actual Study Start Date : January 10, 2019
Estimated Primary Completion Date : January 10, 2021
Estimated Study Completion Date : January 10, 2022


Arm Intervention/treatment
Experimental: With ADRC
Supplementation of fat grafts with ADRC
Procedure: Fat grafts supplemented with ADRC
Isolation of ADRC from fat aspirates and its use for supplementation of fat grafts.

Active Comparator: Structural
Structural fat grafting
Procedure: Structural fat grafting
Fat grafts without supplementation of ADRC




Primary Outcome Measures :
  1. Volumetric analysis of both hemifaces [ Time Frame: Preoperative, 1 month postoperative, 3 months postoperative and 6 months postoperative ]
    Preoperative and 1, 3 and 6-months postoperative 3D-photogrammetry will be performed for volumetric measurements of both hemifaces using Vectra H1 software. Volumetric augmentation will be noticed for each patient by comparing the change between volumes of affected and unaffected hemifaces in the preoperative and 1, 3 and 6 months postoperative periods, which will be considered the retention volume. The percentage of fat graft survival will be determined as a ratio of the retention volume to the preoperative difference between volumes of affected and unaffected hemifaces.


Secondary Outcome Measures :
  1. Number of viable cells [ Time Frame: Intraoperative and immediate postoperative period ]
    Immediately after the surgical procedure the number of viable cells isolated before and after the supplementation of the grafts will be counted using the trypan blue dye exclusion assay in a Neubauer chamber using the light microscope Nikon Eclipse TS100 (Nikon Instruments Inc., NY, USA). Next, immunophenotype characterization of cell populations on passage 1 will be done by flow cytometric analysis with the anti-human antibodies CD29, CD31, CD45, CD90, CD73 and CD105 (Becton, Dickinson and Company, NJ, USA) in a Guava EasyCyte flow cytometer running the Guava Express Plus software (Guava Technologies Hayward, CA, USA).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Unilateral craniofacial microsomia
  • 10 to 18 years old
  • Phenotype: (M0, M1 or M2) and (S1 or S2) according to the OMENS-Plus classification

Exclusion Criteria:

  • Previous facial soft tissue surgery
  • Absence of fat donor site

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03806361


Locations
Layout table for location information
Brazil
Hospital Municipal Infantil Menino Jesus
São Paulo, SP, Brazil, 01329-010
Sponsors and Collaborators
Hospital Sirio-Libanes
Layout table for additonal information
Responsible Party: Daniela S Tanikawa, Principal investigator, Hospital Sirio-Libanes
ClinicalTrials.gov Identifier: NCT03806361    
Other Study ID Numbers: Hospital Sirio Libanes
First Posted: January 16, 2019    Key Record Dates
Last Update Posted: May 12, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Goldenhar Syndrome
Fetal Growth Retardation
Fetal Diseases
Pregnancy Complications
Growth Disorders
Pathologic Processes
Mandibulofacial Dysostosis
Craniofacial Dysostosis
Dysostoses
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Craniofacial Abnormalities
Musculoskeletal Abnormalities
Congenital Abnormalities